Literature DB >> 33106674

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.

Jeffrey Seow1, Carl Graham1, Blair Merrick2, Sam Acors1, Suzanne Pickering1, Kathryn J A Steel3, Oliver Hemmings4, Aoife O'Byrne3, Neophytos Kouphou1, Rui Pedro Galao1, Gilberto Betancor1, Harry D Wilson1, Adrian W Signell1, Helena Winstone1, Claire Kerridge1, Isabella Huettner1, Jose M Jimenez-Guardeño1, Maria Jose Lista1, Nigel Temperton5, Luke B Snell2, Karen Bisnauthsing2, Amelia Moore6, Adrian Green6, Lauren Martinez6, Brielle Stokes6, Johanna Honey6, Alba Izquierdo-Barras6, Gill Arbane7, Amita Patel2, Mark Kia Ik Tan2, Lorcan O'Connell2, Geraldine O'Hara2, Eithne MacMahon2, Sam Douthwaite2, Gaia Nebbia2, Rahul Batra2, Rocio Martinez-Nunez1, Manu Shankar-Hari1,7, Jonathan D Edgeworth1,2, Stuart J D Neil1, Michael H Malim1, Katie J Doores8.   

Abstract

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33106674      PMCID: PMC7610833          DOI: 10.1038/s41564-020-00813-8

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  1 in total

1.  Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.

Authors:  Baweleta Isho; Kento T Abe; Michelle Zuo; Alainna J Jamal; Bhavisha Rathod; Jenny H Wang; Zhijie Li; Gary Chao; Olga L Rojas; Yeo Myong Bang; Annie Pu; Natasha Christie-Holmes; Christian Gervais; Derek Ceccarelli; Payman Samavarchi-Tehrani; Furkan Guvenc; Patrick Budylowski; Angel Li; Aimee Paterson; Feng Yun Yue; Lina M Marin; Lauren Caldwell; Jeffrey L Wrana; Karen Colwill; Frank Sicheri; Samira Mubareka; Scott D Gray-Owen; Steven J Drews; Walter L Siqueira; Miriam Barrios-Rodiles; Mario Ostrowski; James M Rini; Yves Durocher; Allison J McGeer; Jennifer L Gommerman; Anne-Claude Gingras
Journal:  Sci Immunol       Date:  2020-10-08
  1 in total
  456 in total

Review 1.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

2.  Interlaboratory Agreement of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serologic Assays in the Expedited College of American Pathologists Proficiency Testing Program.

Authors:  Danyel H Tacker; Christine Bashleben; Thomas C Long; Elitza S Theel; Vijaya Knight; Kamran Kadkhoda; Daniel D Rhoads; Michael A Linden; Susan L Fink
Journal:  Arch Pathol Lab Med       Date:  2021-05-01       Impact factor: 5.534

3.  Covid-19 transmission modelling of students returning home from university.

Authors:  Paul R Harper; Joshua W Moore; Thomas E Woolley
Journal:  Health Syst (Basingstoke)       Date:  2021-01-17

4.  Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups.

Authors:  Madhusudhanan Narasimhan; Lenin Mahimainathan; Ellen Araj; Andrew E Clark; John Markantonis; Allen Green; Jing Xu; Jeffrey A SoRelle; Charles Alexis; Kimberly Fankhauser; Hiren Parikh; Kathleen Wilkinson; Annika Reczek; Noa Kopplin; Sruthi Yekkaluri; Jyoti Balani; Abey Thomas; Amit G Singal; Ravi Sarode; Alagarraju Muthukumar
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

5.  A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.

Authors:  Yiqi Ruben Luo; Cassandra Yun; Indrani Chakraborty; Alan H B Wu; Kara L Lynch
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

6.  Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.

Authors:  Luca Braga; Hashim Ali; Ilaria Secco; Elena Chiavacci; Guilherme Neves; Daniel Goldhill; Rebecca Penn; Jose M Jimenez-Guardeño; Ana M Ortega-Prieto; Rossana Bussani; Antonio Cannatà; Giorgia Rizzari; Chiara Collesi; Edoardo Schneider; Daniele Arosio; Ajay M Shah; Wendy S Barclay; Michael H Malim; Juan Burrone; Mauro Giacca
Journal:  Nature       Date:  2021-04-07       Impact factor: 49.962

Review 7.  Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection.

Authors:  Seyed Hamid Safiabadi Tali; Jason J LeBlanc; Zubi Sadiq; Oyejide Damilola Oyewunmi; Carolina Camargo; Bahareh Nikpour; Narges Armanfard; Selena M Sagan; Sana Jahanshahi-Anbuhi
Journal:  Clin Microbiol Rev       Date:  2021-05-12       Impact factor: 26.132

Review 8.  Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics.

Authors:  Xiao Tan; Justin H Letendre; James J Collins; Wilson W Wong
Journal:  Cell       Date:  2021-02-10       Impact factor: 41.582

9.  Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?

Authors:  David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

10.  Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile.

Authors:  Jaclyn C Law; Wan Hon Koh; Patrick Budylowski; Jonah Lin; FengYun Yue; Kento T Abe; Bhavisha Rathod; Melanie Girard; Zhijie Li; James M Rini; Samira Mubareka; Allison McGeer; Adrienne K Chan; Anne-Claude Gingras; Tania H Watts; Mario A Ostrowski
Journal:  J Immunol       Date:  2020-11-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.